Mural Oncology plc is Ireland-based clinical-stage oncology company. The Company is a biotechnology company focused on using its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer with the goal of delivering meaningful and clinical benefits to people living with cancer. The Company is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. The lead product candidate, nemvaleukin alfa (nemvaleukin), is an investigational-engineered cytokine fusion protein that selectively binds to the intermediate-affinity interleukin-2 (IL-2) receptor. The Company has also developed engineered therapies targeting the interleukin-18 (IL-18) and interleukin-12 (IL-12) pathways, which have demonstrated therapeutic potential in third-party preclinical and clinical studies.
Código da empresaMURA
Nome da EmpresaMural Oncology PLC
Data de listagemNov 03, 2023
CEOOwen Hughes (Owen)
Número de funcionários116
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 03
Endereço10 Earlsfort Terrace
CidadeDUBLIN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIreland
Código postalD02 T380
Telefone35319058020
Sitehttps://www.muraloncology.com/
Código da empresaMURA
Data de listagemNov 03, 2023
CEOOwen Hughes (Owen)
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados